Prati
Emily Figueiredo Neves Yuki
Emily Figueiredo Neves Yuki
Pesquisador, Hospital das Clínicas da FMUSP
Potvrđena adresa e-pošte na usp.br
Naslov
Citirano
Citirano
Godina
Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
AC Medeiros-Ribeiro, NE Aikawa, CGS Saad, EFN Yuki, T Pedrosa, ...
Nature medicine 27 (10), 1744-1751, 2021
2142021
Two-Week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial
CSR Araujo, AC Medeiros-Ribeiro, CGS Saad, KR Bonfiglioli, ...
Annals of the Rheumatic Diseases 81 (6), 889-897, 2022
652022
Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study
LC Netto, KY Ibrahim, CM Picone, APPS Alves, EV Aniceto, MR Santiago, ...
The Lancet HIV 9 (5), e323-e331, 2022
532022
Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases
NE Aikawa, LVK Kupa, AC Medeiros-Ribeiro, CGS Saad, EFN Yuki, ...
Annals of the Rheumatic Diseases 81 (7), 1036-1043, 2022
452022
Impact of distinct therapies on antibody response to SARS‐CoV‐2 vaccine in systemic lupus erythematosus
EFN Yuki, EF Borba, SG Pasoto, LP Seguro, M Lopes, CGS Saad, ...
Arthritis care & research 74 (4), 562-571, 2022
352022
Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a …
NE Aikawa, LVK Kupa, SG Pasoto, AC Medeiros-Ribeiro, EFN Yuki, ...
The Lancet Rheumatology 4 (2), e113-e124, 2022
302022
Thalidomide and lenalidomide for refractory systemic/cutaneous lupus erythematosus treatment: a narrative review of literature for clinical practice
EFN Yuki, CA Silva, NE Aikawa, R Romiti, CO Heise, E Bonfa, SG Pasoto
JCR: Journal of Clinical Rheumatology 27 (6), 248-259, 2021
272021
Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis
AC Medeiros-Ribeiro, KR Bonfiglioli, DS Domiciano, AY Shimabuco, ...
Annals of the Rheumatic Diseases 81 (5), 710-719, 2022
262022
Systemic autoimmune myopathies: A prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2
SK Shinjo, FHC de Souza, IBP Borges, AM Dos Santos, R Miossi, ...
Rheumatology 61 (8), 3351-3361, 2022
252022
Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases
B Gualano, IR Lemes, RP Silva, AJ Pinto, BC Mazzolani, FI Smaira, ...
Brain, behavior, and immunity 101, 49-56, 2022
252022
Understanding the dynamics of hydroxychloroquine blood levels in lupus nephritis
TN Pedrosa, SG Pasoto, NE Aikawa, EFN Yuki, EF Borba, JCRF Filho, ...
Lupus 29 (6), 560-568, 2020
202020
Strong response after fourth dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccine
NE Aikawa, LVK Kupa, CA Silva, CGS Saad, SG Pasoto, EFN Yuki, ...
Rheumatology (Oxford, England), 2022
192022
Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome
F Signorelli, GGM Balbi, NE Aikawa, CA Silva, LVK Kupa, ...
Lupus 31 (8), 974-984, 2022
162022
Interaction of TNFi and conventional synthetic DMARD in SARS-CoV-2 vaccine response in axial spondyloarthritis and psoriatic arthritis
CGS Saad, MSR Silva, PD Sampaio-Barros, JCB Moraes, CG Schainberg, ...
Joint bone spine 90 (1), 105464, 2023
122023
Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients
CA Silva, AC Medeiros-Ribeiro, LVK Kupa, EFN Yuki, SG Pasoto, ...
Nature communications 13 (1), 5801, 2022
82022
Anti-SARS-CoV-2 immunogenicity decay and incident cases six months after Sinovac-CoronaVac inactivated vaccine in autoimmune rheumatic diseases patients: phase 4 prospective trial
E Bonfa, C Silva, A Medeiros-Ribeiro, L Kupa, E Yuki, SSG Pasoto, ...
82021
Effect of an exercise bout before the booster dose of an inactivated SARS-CoV-2 vaccine on immunogenicity in immunocompromised patients
B Gualano, CGS Saad, SM Sieczkowska, ÍR Lemes, RP da Silva, AJ Pinto, ...
Journal of Applied Physiology 132 (3), 682-688, 2022
72022
Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases
AC Tonacio, T do Nascimento Pedrosa, EF Borba, NE Aikawa, SG Pasoto, ...
PLoS Neglected Tropical Diseases 15 (11), e0010002, 2021
72021
Ankylosing spondylitis and psoriatic arthritis: revisiting screening of latent tuberculosis infection and its follow-up during anti-tumor necrosis factor therapy in an endemic area
AY Shimabuco, AC Medeiros-Ribeiro, R Miossi, KR Bonfiglioli, ...
Clinics 75, 2020
72020
Influenza A/Singapore (H3N2) component vaccine in systemic lupus erythematosus: A distinct pattern of immunogenicity
FF Claudino Formiga, CA Silva, TN Pedrosa, NE Aikawa, SG Pasoto, ...
Lupus 30 (12), 1915-1922, 2021
42021
Sustav trenutno ne može provesti ovu radnju. Pokušajte ponovo kasnije.
Članci 1–20